{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:32:35Z","timestamp":1792589555151,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Combined with cancer screening programs, vaccination against human papillomavirus (HPV) can significantly reduce the high health and economic burden of HPV-related disease in Japan. The objective of this study was to assess the health impact and cost effectiveness of routine and catch-up vaccination of girls and women aged 11\u201326\u2009years with a 4-valent (4vHPV) or 9-valent HPV (9vHPV) vaccine in Japan compared with no vaccination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a mathematical model adapted to the population and healthcare settings in Japan. We compared no vaccination and routine vaccination of 12\u201316-year old girls with 1) 4vHPV vaccine, 2) 9vHPV vaccine, and 3) 9vHPV vaccine in addition to a temporary catch-up vaccination of 17\u201326\u2009years old girls and women with 9vHPV. We estimated the expected number of disease cases and deaths, discounted (at 2% per year) future costs (in 2020 \u00a5) and discounted quality-adjusted life years (QALY), and incremental cost effectiveness ratios (ICER) of each strategy over a time horizon of 100\u2009years. To test the robustness of the conclusions, we conducted scenario and sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over 100\u2009years, compared with no vaccination, 9vHPV vaccination was projected to reduce the incidence of 9vHPV-related cervical cancer by 86% (from 15.24 new cases per 100,000 women in 2021 to 2.02 in 2121). A greater number of cervical cancer cases (484,248) and cancer-related deaths (50,102) were avoided through the described catch-up vaccination program. Routine HPV vaccination with 4vHPV or 9vHPV vaccine prevented 5,521,000 cases of anogenital warts among women and men. Around 23,520 and 21,400 diagnosed non-cervical cancers are prevented by catch-up vaccination among women and men, respectively. Compared with no vaccination, the ICER of 4vHPV vaccination was \u00a5975,364\/QALY. Compared to 4vHPV, 9vHPV\u2009+\u2009Catch-up had an ICER of \u00a51,534,493\/QALY.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A vaccination program with a 9-valent vaccine targeting 12 to 16\u2009year-old girls together with a temporary catchup program will avert significant numbers of cases of HPV-related diseases among both men and women. Furthermore, such a program was the most cost effective among the vaccination strategies we considered, with an ICER well below a threshold of \u00a55000,000\/QALY.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-020-05632-0","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T12:13:16Z","timestamp":1609935196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-5999","authenticated-orcid":false,"given":"Palmer","family":"Cody","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Tobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elamin H.","family":"Elbasha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"5632_CR1","unstructured":"National Cancer Registry, Japan [https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html ]."},{"issue":"9","key":"5632_CR2","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/ijc.32014","volume":"144","author":"M Utada","year":"2019","unstructured":"Utada M, Chernyavskiy P, Lee WJ, Franceschi S, Sauvaget C, de Gonzalez AB, et al. Increasing risk of uterine cervical cancer among young Japanese women: comparison of incidence trends in Japan, South Korea and Japanese-Americans between 1985 and 2012. Int J Cancer. 2019;144(9):2144\u201352.","journal-title":"Int J Cancer"},{"issue":"4","key":"5632_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ijc.30716","volume":"141","author":"C de Martel","year":"2017","unstructured":"de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664\u201370.","journal-title":"Int J Cancer"},{"issue":"1","key":"5632_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12879-020-4801-x","volume":"20","author":"M Kawado","year":"2020","unstructured":"Kawado M, Hashimoto S, Ohta A, Oba MS, Uehara R, Taniguchi K, et al. Estimating nationwide cases of sexually transmitted diseases in 2015 from sentinel surveillance data in Japan. BMC Infect Dis. 2020;20(1):77.","journal-title":"BMC Infect Dis"},{"key":"5632_CR5","volume-title":"Human papillomavirus and related diseases in United Kingdom. Summary report 17 June 2019. In., vol. 2020","author":"L Bruni","year":"2019","unstructured":"Bruni L, Albero G, Serrano B, Mena M, G\u00f3mez D, Mu\u00f1oz J, et al. Human papillomavirus and related diseases in United Kingdom. Summary report 17 June 2019. In., vol. 2020. United Kingdom: ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre); 2019."},{"key":"5632_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12913-015-0776-5","volume":"15","author":"E Hayata","year":"2015","unstructured":"Hayata E, Seto K, Haga K, Kitazawa T, Matsumoto K, Morita M, et al. Cost of illness of the cervical cancer of the uterus in Japan--a time trend and future projections. BMC Health Serv Res. 2015;15:104.","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"5632_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/jjco\/hyq036","volume":"40","author":"C Hamashima","year":"2010","unstructured":"Hamashima C, Aoki D, Miyagi E, Saito E, Nakayama T, Sagawa M, et al. The Japanese guideline for cervical cancer screening. Jpn J Clin Oncol. 2010;40(6):485\u2013502.","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"5632_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229924","volume":"15","author":"Y Miki","year":"2020","unstructured":"Miki Y, Tase T, Tokunaga H, Yaegashi N, Ito K. Cervical cancer screening rates before and after the great East Japan earthquake in the Miyagi prefecture, Japan. PLoS One. 2020;15(3):e0229924.","journal-title":"PLoS One"},{"key":"5632_CR9","unstructured":"PharmaJapan [https:\/\/pj.jiho.jp\/article\/242550]."},{"issue":"9894","key":"5632_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S0140-6736(13)61831-0","volume":"382","author":"S Gilmour","year":"2013","unstructured":"Gilmour S, Kanda M, Kusumi E, Tanimoto T, Kami M, Shibuya K. HPV vaccination programme in Japan. Lancet (London, England). 2013;382(9894):768.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"5632_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/14760584.2019.1584040","volume":"18","author":"S Ikeda","year":"2019","unstructured":"Ikeda S, Ueda Y, Yagi A, Matsuzaki S, Kobayashi E, Kimura T, et al. HPV vaccination in Japan: what is happening in Japan? Expert Rev Vaccines. 2019;18(4):323\u20135.","journal-title":"Expert Rev Vaccines"},{"issue":"9987","key":"5632_CR12","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1016\/S0140-6736(15)61152-7","volume":"385","author":"SJ Hanley","year":"2015","unstructured":"Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571.","journal-title":"Lancet"},{"issue":"12","key":"5632_CR13","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(18)30573-4","volume":"19","author":"Y Ueda","year":"2018","unstructured":"Ueda Y, Yagi A, Ikeda S, Enomoto T, Kimura T. Beyond resumption of the Japanese Government's recommendation of the HPV vaccine. Lancet Oncol. 2018;19(12):1563\u20134.","journal-title":"Lancet Oncol"},{"issue":"1","key":"5632_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.vhri.2013.02.001","volume":"2","author":"K Yamabe","year":"2013","unstructured":"Yamabe K, Singhal PK, Abe M, Dasbach EJ, Elbasha EH. The cost-effectiveness analysis of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) for females in Japan. Value Health Reg Issues. 2013;2(1):92\u20137.","journal-title":"Value Health Reg Issues"},{"issue":"2","key":"5632_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1471-0528.2011.03036.x","volume":"119","author":"N Yamamoto","year":"2012","unstructured":"Yamamoto N, Mori R, Jacklin P, Osuga Y, Kawana K, Shibuya K, et al. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. BJOG. 2012;119(2):177\u201386.","journal-title":"BJOG"},{"issue":"19","key":"5632_CR16","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1016\/j.vaccine.2018.03.024","volume":"36","author":"SS Ng","year":"2018","unstructured":"Ng SS, Hutubessy R, Chaiyakunapruk N. Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination. Vaccine. 2018;36(19):2529\u201344.","journal-title":"Vaccine"},{"issue":"6","key":"5632_CR17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1080\/21645515.2016.1140288","volume":"12","author":"HW Chesson","year":"2016","unstructured":"Chesson HW, Markowitz LE, Hariri S, Ekwueme DU, Saraiya M. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: estimates from a simplified transmission model. Hum Vaccin Immunother. 2016;12(6):1363\u201372.","journal-title":"Hum Vaccin Immunother"},{"issue":"18","key":"5632_CR18","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1073\/pnas.1515528113","volume":"113","author":"DP Durham","year":"2016","unstructured":"Durham DP, Ndeffo-Mbah ML, Skrip LA, Jones FK, Bauch CT, Galvani AP. National- and state-level impact and cost-effectiveness of nonavalent HPV vaccination in the United States. Proc Natl Acad Sci. 2016;113(18):5107\u201312.","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"5632_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12879-016-1483-5","volume":"16","author":"L Boiron","year":"2016","unstructured":"Boiron L, Joura E, Largeron N, Prager B, Uhart M. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis. 2016;16(1):153.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"5632_CR20","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/ijc.28541","volume":"134","author":"M Drolet","year":"2014","unstructured":"Drolet M, Laprise JF, Boily MC, Franco EL, Brisson M. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134(9):2264\u20138.","journal-title":"Int J Cancer"},{"issue":"2","key":"5632_CR21","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/S2468-2667(16)30019-6","volume":"1","author":"KT Simms","year":"2016","unstructured":"Simms KT, Laprise J-F, Smith MA, Lew J-B, Caruana M, Brisson M, et al. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health. 2016;1(2):e66\u201375.","journal-title":"Lancet Public Health"},{"key":"5632_CR22","unstructured":"Burger EA, Portnoy A, Campos NG, Sy S, Regan C, Kim JJ. Choosing the optimal HPV vaccine: the health impact and economic value of the nonavalent and bivalent HPV vaccines in 48 Gavi-eligible countries. Int J Cancer. n\/a(n\/a)."},{"issue":"1","key":"5632_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12879-019-4108-y","volume":"19","author":"S Datta","year":"2019","unstructured":"Datta S, Pink J, Medley GF, Petrou S, Staniszewska S, Underwood M, et al. Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK. BMC Infect Dis. 2019;19(1):552.","journal-title":"BMC Infect Dis"},{"issue":"42","key":"5632_CR24","doi-asserted-by":"publisher","first-page":"6858","DOI":"10.1016\/j.vaccine.2010.08.030","volume":"28","author":"EH Elbasha","year":"2010","unstructured":"Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858\u201367.","journal-title":"Vaccine"},{"issue":"1","key":"5632_CR25","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3201\/eid1301.060438","volume":"13","author":"EH Elbasha","year":"2007","unstructured":"Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28\u201341.","journal-title":"Emerg Infect Dis"},{"key":"5632_CR26","unstructured":"HIV & Sex Survey, Japan. 1999."},{"key":"5632_CR27","unstructured":"Education JAfS: 8th Survey Report on Youth Sexual Behavior: Junior High School Students, High School Students, and University Students in Japan. In.; 2018."},{"key":"5632_CR28","unstructured":"Japanese Ministry of Health, Labor and Welfare. Demographic data [https:\/\/www.mhlw.go.jp\/english\/]."},{"issue":"12","key":"5632_CR29","first-page":"520","volume":"45","author":"M Ono-Kihara","year":"2002","unstructured":"Ono-Kihara M, Kihara M, Yamazaki H. Sexual practices and the risk for HIV\/STDs infection of youth in Japan. Jpn Med Assoc J. 2002;45(12):520\u20135.","journal-title":"Jpn Med Assoc J"},{"key":"5632_CR30","unstructured":"Japanese Ministry of Health Labor and Welfare. National Health Insurance fee schedule. In. Tokyo, Japan; 2020."},{"key":"5632_CR31","unstructured":"Overview of the National Life Basic Survey [https:\/\/ganjoho.jp\/reg_stat\/statistics\/dl_screening\/index.html#a16]."},{"issue":"3","key":"5632_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11136-015-1108-2","volume":"25","author":"T Shiroiwa","year":"2016","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Igarashi A, Noto S, Saito S, et al. Japanese population norms for preference-based measures: EQ-5D-3L, EQ-5D-5L, and SF-6D. Qual Life Res. 2016;25(3):707\u201319.","journal-title":"Qual Life Res"},{"key":"5632_CR33","unstructured":"Research Team on cost-effectiveness evaluation TLTF: Guideline for Preparing Cost-Effectiveness Evaluation to the Central Social Insurance Medical Council In.; 2019."},{"issue":"1","key":"5632_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1003968","volume":"11","author":"I Andrianakis","year":"2015","unstructured":"Andrianakis I, Vernon IR, McCreesh N, McKinley TJ, Oakley JE, Nsubuga RN, et al. Bayesian history matching of complex infectious disease models using emulation: a tutorial and a case study on HIV in Uganda. PLoS Comput Biol. 2015;11(1):e1003968.","journal-title":"PLoS Comput Biol"},{"issue":"1","key":"5632_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1478-7547-11-22","volume":"11","author":"T Shiroiwa","year":"2013","unstructured":"Shiroiwa T, Igarashi A, Fukuda T, Ikeda S. WTP for a QALY and health states: more money for severer health states? Cost Effect Resource Allocation. 2013;11(1):22.","journal-title":"Cost Effect Resource Allocation"},{"key":"5632_CR36","doi-asserted-by":"crossref","unstructured":"Konno R, Sasagawa T, Fukuda T, Van Kriekinge G, Demarteau N. Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer. 2010;20(3).","DOI":"10.1111\/IGC.0b013e3181d189b8"},{"issue":"4","key":"5632_CR37","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1016\/S2468-2667(20)30010-4","volume":"5","author":"KT Simms","year":"2020","unstructured":"Simms KT, Hanley SJB, Smith MA, Keane A, Canfell K. Impact of HPV vaccine hesitancy on cervical cancer in Japan: a modelling study. Lancet Public Health. 2020;5(4):e223\u201334.","journal-title":"Lancet Public Health"},{"key":"5632_CR38","unstructured":"Number of regular vaccinations [https:\/\/www.mhlw.go.jp\/topics\/bcg\/other\/5.html]."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05632-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-020-05632-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-020-05632-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T15:04:51Z","timestamp":1610204691000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-020-05632-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5632"],"URL":"https:\/\/doi.org\/10.1186\/s12879-020-05632-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"27 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The 4-valent HPV vaccine, Gardasil\u00ae [Human Papillomavirus (Types 6, 11, 16,18) Recombinant Vaccine] and 9-valent HPV vaccine, Silgard9\u00ae [Human Papillomavirus (HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58)] were developed and are currently marketed by Merck & Co., Inc., Kenilworth, NJ, USA. CP and EE are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. TK and AM are employees of MSD K.K., Tokyo, Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}